Apixaban + Unfractionated Heparin (UFH) + Warfarin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Deep Vein Thrombosis
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Trial Timeline
Jan 1, 2013 → Sep 1, 2014
NCT ID
NCT01780987About Apixaban + Unfractionated Heparin (UFH) + Warfarin
Apixaban + Unfractionated Heparin (UFH) + Warfarin is a phase 3 stage product being developed by Pfizer for Deep Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01780987. Target conditions include Deep Vein Thrombosis, Pulmonary Embolism.
What happened to similar drugs?
4 of 11 similar drugs in Deep Vein Thrombosis were approved
Approved (4) Terminated (2) Active (7)
🔄Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3
🔄Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01780987 | Phase 3 | Completed |
Competing Products
20 competing products in Deep Vein Thrombosis